학술논문

Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2
Document Type
article
Source
Proceedings of the National Academy of Sciences of the United States of America. 120(2)
Subject
Theory Of Computation
Biochemistry and Cell Biology
Biological Sciences
Medicinal and Biomolecular Chemistry
Chemical Sciences
Built Environment and Design
Information and Computing Sciences
Design
Emerging Infectious Diseases
Vaccine Related
Biodefense
Prevention
Lung
Infectious Diseases
Pneumonia & Influenza
Development of treatments and therapeutic interventions
5.1 Pharmaceuticals
Generic health relevance
Humans
SARS-CoV-2
COVID-19
Crystallography
Pandemics
Ligands
Molecular Docking Simulation
Protease Inhibitors
Antiviral Agents
coronavirus
macrodomain
virtual screening
fragment-based drug discovery
Language
Abstract
The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. While small-molecule inhibitors of Mac1 have great therapeutic potential, at the outset of the COVID-19 pandemic, there were no well-validated inhibitors for this protein nor, indeed, the macrodomain enzyme family, making this target a pharmacological orphan. Here, we report the structure-based discovery and development of several different chemical scaffolds exhibiting low- to sub-micromolar affinity for Mac1 through iterations of computer-aided design, structural characterization by ultra-high-resolution protein crystallography, and binding evaluation. Potent scaffolds were designed with in silico fragment linkage and by ultra-large library docking of over 450 million molecules. Both techniques leverage the computational exploration of tangible chemical space and are applicable to other pharmacological orphans. Overall, 160 ligands in 119 different scaffolds were discovered, and 153 Mac1-ligand complex crystal structures were determined, typically to 1 Å resolution or better. Our analyses discovered selective and cell-permeable molecules, unexpected ligand-mediated conformational changes within the active site, and key inhibitor motifs that will template future drug development against Mac1.